Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2347${count})

  • LRRK2 Biology Consortium, 2017
    Characterization of Leukocytes as Biomarkers for LRRK2 and Autophagy in Parkinson's Disease

    Study Rationale:

    To avoid accumulation of products that may cause toxicity, neurons rely on a series of highly efficient mechanisms of quality control. It has been proposed that, in those with...

  • Target Advancement Program, 2017
    Neuroprotective Effects of Endosulfine-alpha in Parkinson's Disease

    Study Rationale:
    Evidence suggests that alpha-synuclein can cause neuron death in Parkinson's disease (PD) by forming clusters (or aggregates) on the surface of small structures inside the cell called...

  • Target Advancement Program, 2017
    Validation of USP30 as a Therapeutic Target for Parkinson's Disease Modification

    Study Rationale:
    Mitochondria provide energy for neurons to function and survive. Evidence suggests that individuals with Parkinson's disease (PD) have poorly functioning mitochondria, such that the...

  • Target Advancement Program, 2017
    Farnesoid X Receptor to Reduce Neuroinflammation

    Study Rationale:
    Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we...

  • Therapeutic Pipeline Program, 2017
    Small-Molecule Inhibitor of Alpha-Synuclein Propagation in the Treatment of Parkinson's Disease

    Study Rationale:
    The notion of misfolded alpha-synuclein (alpha-syn) aggregates moving from neuron-to-neuron is a mechanism that is gaining widespread acceptance as a central mechanism in the...

  • Therapeutic Pipeline Program, 2017
    Pre-clinical Development of LBT-3627, a Potential Neuroprotective and Anti-inflammatory Therapy for Parkinson's Disease

    Study Rationale:
    Adaptive and innate immune responses play important roles in neuroinflammation and can be harnessed to improve outcomes in Parkinson's disease (PD). Daily administration of LBT-3627...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.